Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498811 | 0.85 | HPGD (0.48) | EPHX2CA2ROCK2ROCK1MAPT | |
| SCHEMBL6506168 | 0.79 | PPARD (0.61) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL305177 | 0.77 | PTPN1 (0.49) | EPHX2CA2PPARDPPARAPPARG | |
| SCHEMBL8821819 | 0.76 | EPHX2 (0.57) | EPHX2PPARG | |
| SCHEMBL6502341 | 0.76 | EPHX2 (0.44) | EPHX2PPARGMAPTTP53 | |
| SCHEMBL9943344 | 0.75 | P2RX7 (0.43) | EPHX2CA2PPARGROCK2ROCK1 | |
| SCHEMBL6504802 | 0.74 | HTT (0.55) | CA2PPARGROCK2ROCK1MAPT | |
| SCHEMBL6496500 | 0.74 | HPGD (0.53) | CA2PPARDPPARAPPARGROCK2 | |
| SCHEMBL6506747 | 0.73 | CA2 (0.48) | CA2PPARGROCK2ROCK1MAPT | |
| SCHEMBL6502439 | 0.73 | PPARD (0.61) | PPARDPPARAPPARGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-2346498-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | Metabolex Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045361-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-7301050-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICAL N.V. (BE) | 2007-11-27 | — | — | US | disclosed |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | EPHX2 3889/4885CA2 4567/4885PPARD 345/4885 |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | EPHX2 3889/4885CA2 4567/4885PPARD 345/4885 |
| US-20050124698-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | EPHX2 2467/4885CA2 2857/4885PPARD 3/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | EPHX2 3889/4885CA2 4567/4885PPARD 345/4885 |
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | EPHX2 3889/4885CA2 4567/4885PPARD 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.